Adam M. Brufsky, MD, PhD
Advertisement
Articles by Adam M. Brufsky, MD, PhD
Advertisement
Latest Updated Articles
Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN PathwayPublished: July 2nd 2024 | Updated:
Next-Generation Sequencing Platforms for Late-Stage HR+ Breast CancerPublished: July 27th 2022 | Updated:
- Adjuvant Abemaciclib in High-Risk HR+/HER2-, Node+ BC: The monarchE Trial
Published: August 3rd 2022 | Updated:
- Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Published: July 9th 2024 | Updated:
Audience Q&A: Future Directions in Breast Cancer CarePublished: August 31st 2022 | Updated:
DESTINY-Breast04: T-DXd in HER2-Low Metastatic Breast CancerPublished: August 24th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5